Navigation Links
Merck's Pain Reliever Arcoxia Rejected by US Federal Advisory Panel

An advisory panel of the United States Food and Drug Administration (FDA) has rejected pharmaceutical giant Merck's bid to market Arcoxia,// a new osteoarthritis medication following concerns that it may carry cardiovascular risks.

Osteoarthritis is a joint disease that mostly affects cartilage. Cartilage is the slippery tissue that covers the ends of bones in a joint.

While healthy cartilage allows bones to glide over each other and helps absorb shock of movement, in osteoarthritis, the top layer of cartilage breaks down and wears away.

This allows bones under the cartilage to rub together. The rubbing causes pain, swelling, and loss of motion of the joint.

Merck's Arcoxia is in the class of non-steroidal anti-inflammatory drugs (NSAIDs) known as COX-2 inhibitors.

It had to pull yet another CoX-2 inhibitor Vioxx from the US market in 2004, also following evidence that it increased the patients' risk of heart attacks and strokes.

G.D.Searle and Company too withdrew a COX-2 inhibitor, Bextra because of similar concerns.

These newly developed drugs for treatment of inflammation selectively block an enzyme called COX-2. Blocking this enzyme impedes the production of the chemical messengers (prostaglandins) that cause the pain and swelling resulting from arthritis inflammation.

And they are supposed to be gentler on the stomach, making it easier for patients than traditional pain relievers. But then one has to contend with serious side-effects.

The FDA advisory panel on Thursday rejected by a 20-to-1 margin the Merck's new formulation, Arcoxia.

"We got what appears to be a very clear vote advising us against approval," said Robert Meyer, director of FDA's office of drug evaluation.

Dr. David Graham, a leading critic of the now withdrawn Vioxx, told the panel that Arcoxia might increase substantially the risk of stroke and heart attack and was no more e
'"/>




Page: 1 2

Related medicine news :

1. Acid Test - Glaxos Cervarix, and Mercks Gardasil, Compete
2. Ranbaxy in Fray to Buy Mercks Generic Drugs Unit
3. The Effect Of Pain Relievers In Treating Kids With Migraine Questioned
4. Hypnotherapy can be a Pain Reliever
5. FDA Proposes Stringent Warnings Labels for Pain Relievers
6. Arcoxia Slammed –Nothing Better Than Vioxx Says FD
7. Testosterone patch for women Rejected For safety Reasons
8. Federal Government Has to do a lot to prevent spread of HIV
9. New Study Conducted To Evaluate The Success Of The Federal governments Funds For HIV/AIDS
10. Sunscreen Blocking UVA Radiation Receives Federal Approval
11. Imperative to Extend Reach of Federal Health Insurance Schemes for children
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Merck Pain Reliever Arcoxia Rejected Federal Advisory Panel

(Date:12/25/2014)... The report “TS-1 (Colorectal Cancer) – Forecast ... treatment landscape, unmet needs, current pipeline and commercial opportunities ... drug which is typically used for treating colorectal cancer. ... treating gastric cancer and pancreatic cancer. TS-1 is composed ... first approved in 1999 in Japan for the treatment ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying women’s ... discounted prom dresses, most of which are priced under ... company, the promotion is valid until Jan. 22, 2015; ... UK market. , The prom dresses in this new ... A-line strapless, empire strapless chiffon, one shoulder, floor-length, V-neck ...
(Date:12/25/2014)... December 25, 2014 Helen Harris’ RP ... Woodland Hills, California after an 8 year battle with ... Christmas Eve evening in her home in Woodland Hills ... breast cancer. , As the founder ... years, she pioneered and championed many of today's greatest ...
(Date:12/25/2014)... THURSDAY, Dec. 25, 2014 (HealthDay News) -- The risk ... the holidays, so you need to be extra cautious, ... Day, we see a significant increase in patients coming ... at the Suffolk County Volunteer Firefighters Burn Center of ... celebrations should be full of joy, but if not ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 AngelWeddingDress.com tries ... to the online realm. Today, the business has introduced ... a site-wide prom dress promotion. , The new prom ... each and every dress lover. They are specially designed ... 2015 prom dresses should visit its website before ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Don't Let Burns Mar Your Holidays 2Health News:Angelweddingdress 2015 Prom Dresses Online Now 2
... 29 A federal court in San Francisco has ... Inc. ("Pfizer") about the marketing of the prescription drugs ... In re Bextra and Celebrex Marketing, Sales Practices, ... 1699, pending in the United States District Court for ...
... Response, an unprecedented partnership created to help ensure the continued ... emergency, has been put on Alert Status as concerns grow ... in the United States."Americans need to know that the medicines ... said Billy Tauzin, president and CEO of the Pharmaceutical Research ...
... services hires former Ernst & Young and Capgemini ... Virtify, Inc. ( www.virtify.com ), ... for life sciences, today announced the addition of ... executive, as executive vice president of commercial operations. ...
... On 22 and 23 June 2009, the Prostate ... be held in the Beurs van Berlage in ... from laboratory, clinical or population studies into clinical ... , The European Association of Urology (EAU) provides ...
... zebrafish could hold the key to stem cell treatments for ... have found that these fish are able to produce motor ... speaking, walking and breathing in humans when they repair ... small molecules with a view to finding drugs that could ...
... OneBeacon Professional Partners, a member of OneBeacon Insurance ... two new comprehensive management liability insurance solutions designed ... The Health Care Organization Management Liability product ... nonprofit organizations that offer health care services including: ...
Cached Medicine News:Health News:$89 Million Proposed Class Action Settlement Provides Consumers and Insurers With Money Back for Celebrex and Bextra Purchases and Reimbursements 2Health News:Rx Response Raised to 'Alert Status' in Response to Growing Swine Flu Threat 2Health News:Rx Response Raised to 'Alert Status' in Response to Growing Swine Flu Threat 3Health News:Building on Growth, Virtify Adds to Executive Team and Expands Commercial Operations 2Health News:Building on Growth, Virtify Adds to Executive Team and Expands Commercial Operations 3Health News:Building on Growth, Virtify Adds to Executive Team and Expands Commercial Operations 4Health News:EAU Research Foundation organizes meeting in Amsterdam highlighting translational research results 2Health News:Zebrafish offer clues to treatments for motor neurone disease 2Health News:OneBeacon Professional Partners Expands Directors & Officers Coverage for Health Care Organizations, Nonprofit Organizations 2Health News:OneBeacon Professional Partners Expands Directors & Officers Coverage for Health Care Organizations, Nonprofit Organizations 3Health News:OneBeacon Professional Partners Expands Directors & Officers Coverage for Health Care Organizations, Nonprofit Organizations 4
(Date:12/24/2014)... 24, 2014  Actavis plc (NYSE: ... received a complete response letter from the U.S. ... Drug Application (NDA) for the fixed-dose combination (FDC) ... hypertension.   Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... the receipt of a complete response letter, Actavis ...
(Date:12/24/2014)... CHENGDU, China, Dec. 24, 2014 /PRNewswire/  -- Tianyin ... a pharmaceutical company that specializes in the patented ... and active pharmaceutical ingredients (API) released unaudited preliminary ... year 2015. Fiscal Year 2015 Ended ... was $9.7 million compared with $14.7 million in ...
(Date:12/24/2014)... N.J. , Dec. 24, 2014 ... a late-stage biopharmaceutical company developing products that address ... oncology and biodefense, announced today that on December ... public offering. The Company raised approximately ... and intends to use the net proceeds from ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
... 2012  GP Strategies Corporation (NYSE: GPX ), ... sales and technical training, e-Learning solutions, management consulting and ... CFO Sharon Esposito-Mayer will speak at the Robert W. ... 10:55 a.m. ET. The conference will be held at ...
... nation,s leader in pain medication monitoring, commends the ... For Patients On Long-Term Opioid Therapy," unveiled Friday ... Academy of Pain Medicine,s (AAPM) 28th Annual Meeting ... seek to answer key questions that physicians may ...
Cached Medicine Technology:Ameritox Supports New Expert Consensus Recommendations For Patients on Long-Term Opioid Therapy 2Ameritox Supports New Expert Consensus Recommendations For Patients on Long-Term Opioid Therapy 3
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
... Central platform with integrated neck. Piston ... utilizing an internal spring to recoil ... Cutting Block fits into precision milled ... blades sized 6.25 - 9.0mm. Designed ...
... Central platform with integrated neck. Piston ... utilizing an internal spring to recoil ... Cutting Block fits into precision milled ... blades sized 6.25 - 9.0mm. Designed ...
Adjustable piston accommodates 7-9mm trephine blade. Complete punch includes base plate, piston carrier, piston for 7 - 9mm trephine blades and 18mm diameter Teflon block. Designed for accurate donor...
Medicine Products: